Relative bioavailability and bioequivalence study of theophylline sustained release formulations

Arzneimittel-Forschung/Drug Research

Volumn 53, Issue 9, 2003, Pages 635-639

  Vergin, Hartmut ^a   Mahr, Gerhard ^b   Winterhalter, Bernd ^a   Wigand, Rainer ^c  

^a Pharmacia GmbH   (Germany)

^b mpc   (Germany)

^c GOETHE UNIVERSITY   (Germany)

Author keywords

CAS 58 55 9; Theophyllin 400 retard Heumann, bioequivalence, relative bioavailability; Theophylline, bioequivalence, relative bioavailability, sustained release formulations

Indexed keywords

THEOPHYLLINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; EUPHORIA; HEART PALPITATION; HUMAN; HUMAN EXPERIMENT; MALE; NAUSEA; NORMAL HUMAN; POLLAKISURIA; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SUSTAINED RELEASE PREPARATION;

EID: 0141426814     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1297160     Document Type: Article

References (11)

1. Weinberger, M. M., Riegelman, S., Evaluation of oral bronchodilator therapy in asthmatic children. J. Ped. 64, 421 (1974)
2. Mitenko, P. A., Ogilvie, R. I., Rational intravenous doses of theophylline. N. Engl. J. Med. 239, 600 (1973)
3. Levy, G., Koysooko, R., Pharmacokinetic analysis of the effect of theophylline on pulmonary function in asthmatic children. J. Pediatr. 86, 789 (1975)
4. McKee, M., Haggerty, R. J., Toxic hazard aminophylline poisoning. N. Engl. J. Med. 256, 956 (1957)
5. Glynn-Barnhart, A., Hill, M., Szefler, S., Sustained Release Theophylline Preparations. Drugs 35, 711 (1988)
6. Gibaldi, M., Perrier, D., Pharmacokinetics, Marcel Dekker Inc., New York (1975)
7. Heinzel, G., Woloszczak, B., Thomann, P., Pharmacokinetic and pharmacodynamic data analysis system for the PC. Gustav Fischer Verlag, Stuttgart - Jena (1993)
8. Wagner, J. G., Pharmacokinetic absorption plots from oral data alone or oral/intravenous data and an exact Loo-Riegelman equation. J. Pharm. Sci. 72, 838 (1983)
9. Blume, H., Mutschler, E. (eds.), Bioäquivalenz, Teil 3, Retard-Arzneimittel I, Theophyllin, pp. 1-2, Govi Verlag, Eschborn (1993)
10. Jackson, S. H. D., Johnston, A., Woollard, R. et al., Circadian variations in theophylline absorption during chronic dosing with a slow release theophylline preparation and the effect of clock time of dosing. Br. J. Clin. Pharmacol. 26, 73 (1988)
11. Weinberger, M., Hendeles, L., Bighley, L., The relationship of product formulation to absorption of oral theophylline. N. Engl. J. Med. 299, 852 (1978)